Purpose The recent increase in the incidence of ductal carcinoma in situ (DCIS) has sparked debate over the classification and treatment of this disease. Although DCIS is considered a precursor lesion to invasive breast cancer, some DCIS may have more or less risk than is realized. In this study, we characterized the immune microenvironment in DCIS to determine if immune infiltrates are predictive of recurrence. Methods Fifty-two cases of high-grade DCIS (HG-DCIS), enriched for large lesions and a history of recurrence, were age matched with 65 cases of non-high-grade DCIS (nHG-DCIS). Immune infiltrates were characterized by single-or dual-color staining of FFPE sections for the following antigens: CD4, CD8, CD20, FoxP3, CD68, CD115, Mac387, MRC1, HLA-DR, and PCNA. Nuance multispectral imaging software was used for image acquisition. Protocols for automated image analysis were developed using CellProfiler. Immune cell populations associated with risk of recurrence were identified using classification and regression tree analysis.
Introduction
Ductal carcinoma in situ (DCIS) is a non-obligate precursor of invasive breast carcinoma that is characterized by the confinement of proliferating ductal cells, with malignant features, to within the basement membrane of mammary ducts [1] . Pure DCIS, as well as DCIS with micro-invasion (DCIS lesions with an invasive component of 0.1 cm or less), is typically thought to have a very low risk of recurrence and death [2] [3] [4] . The risk for development of a potentially lethal invasive cancer, however, is thought to be sufficient to warrant an aggressive surgical approach. As such, treatment includes surgical excision and generally radiation therapy or mastectomy. For hormone receptorpositive DCIS, risk reducing endocrine therapy is offered unless bilateral mastectomy is performed, while chemotherapy is not offered.
While aggressive disease comprises only a small percentage of DCIS cases, less aggressive DCIS tumors are often treated with the same therapies, resulting in the overtreatment of many DCIS patients [5] . At the other extreme, however, is the infrequent but equally concerning potential for undertreatment. Recently, an evaluation of 100,000 cases of DCIS revealed that there is a small group of women diagnosed with DCIS that develop metastatic disease without first developing an invasive cancer recurrence who are at risk of dying from their disease [6] . Importantly, current treatments do not prevent death. We therefore need the ability to characterize the highest risk DCIS lesions and their underlying biology so that we can develop and test more appropriate treatments.
DCIS lesions with a greater chance of disease recurrence or progression are categorized by a number of biological factors including high histologic nuclear grade and comedonecrosis [7] [8] [9] [10] [11] [12] , tumor size and pathological density [13, 14] , and palpability [15] . The University of Southern California/Van Nuys Prognostic Index (USC/ VNPI) was devised by combining four statistically significant independent prognostic factors for local recurrence: tumor size, margin width, age, and pathological classification (determined by nuclear grade and the presence or absence of comedo-type necrosis) [16, 17] . While these associations have proven beneficial in categorizing DCIS lesions, and directing local therapy, these markers are not sufficient to identify the group at risk of death from their DCIS nor to predict what therapy might prevent that event.
The tumor immune microenvironment clearly plays a role in the progression of invasive breast cancer. Tumorassociated macrophages (TAMs), regulatory T cells (Treg), type 2 helper T cells (Th2), and myeloid-derived suppressor cells (MDSC) are associated with a suppressive immune microenvironment and poor outcomes, while other cells such as cytotoxic T cells (Tc), type 1 helper T cells (Th1), and natural killer cells (NK) are associated with an antitumor immune microenvironment and good outcomes [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] . In contrast, the immune landscape of DCIS has not been well characterized. Increased inflammation in DCIS is associated with high nuclear grade, HER2 positivity, and extent of lesions [30, 31] . FoxP3? Tregs have been identified in DCIS lesions, although they were not associated with grade [32] . Esserman and coworkers found that CD68 ? macrophages were associated with large, pathologically dense, high-grade DCIS lesions with comedonecrosis [13] . High-grade DCIS lesions are also associated with a macrophage response signature [33] .
In this study, we characterized and compared the immune microenvironments in high-grade DCIS (HG-DCIS) and non-high-grade DCIS (nHG-DCIS) and sought to determine if immune infiltrates are predictive of recurrence and metastasis.
Materials and methods

Sample collection
One hundred and seventeen archived paraffin blocks (collected between 1994 and 2014) were retrieved from the UCSF breast oncology program tumor bank with IRB approval (see CONSORT Diagram, Fig. 1 ). Fifty-two cases of high-grade DCIS (HG-DCIS), enriched for large lesions and a history of recurrence, were age-and size-matched with 65 cases of non-high-grade DCIS (nHG-DCIS). This study was conducted to better understand the biology/immunology of high-grade, high-risk DCIS. Since we selected for a cohort of high-grade DCIS and an age-and sizematched cohort of non-high-grade DCIS, the overall study population is biased towards more high-grade cases and larger lesions compared to a non-selected population.
Pathologic [16, 17] . Breast density was determined radiographically and classified into the standard four BI-RADS groups by a radiologist. DCIS density was determined from H&E-stained slides as previously described [13] .
Manual TIL counts
Tumor infiltrating lymphocytes (TIL) were visually identified by a pathologist on 5-lm H&E-stained sections, based on morphology and size. TILs identified within the DCIS lesions (itTILs) were manually counted in 10 high power fields (HPF; 400X) and the average number of TILs per HPF was calculated for each case. Stromal TILs (stTILs) were visually estimated as a percentage of total stroma per section and assigned a score of 1-4 (1: B1%; 2: [1 and B5%; 3: [5 and B10%; 4: [10%).
Immunohistochemistry
Antibodies and their respective dilutions used in this study are listed in Table 1 . Formalin-fixed, paraffin-embedded tumor blocks were cut into 5-lm sections, deparaffinized in xylene and rehydrated using graded ethanol. Antigen retrieval was performed with pressure cooking in 10 mM citrate buffer for 10 min. This was followed by application of an endogenous enzyme block and subsequent protein block to prevent non-specific antibody binding. Singlemarker stains were performed with a standard streptavidinbiotin peroxidase method using the Vectastain ABC-HRP labeling kit (Vector Labs) and DAB as a substrate. Single color stains were performed for the following antigens: CD115 and FoxP3. Two-color immunohistochemistry was performed using the EnVision G/2 Doublestain System (DAB?/Permanent Red; Dako). Dual-marker staining was performed for the following antigen pairs: CD68/PCNA, CD68/MAC387, CD68/MRC1, CD8/HLA-DR, and CD4/ CD20. Slides were counterstained with hematoxylin to aid identification of nuclei in subsequent image analyses.
Multispectral imaging
For each case, 3 hot spots based on CD68/Mac387 staining were manually identified by a pathologist and marked on 10 consecutive sections. Images were captured from these marked regions for each single-or dual-stained slide. Using CD8/HLADR staining as the criterion to identify hotspots resulted in similar results (data not shown). Two colors (DAB and hematoxylin) on single-stained slides or three colors (DAB, Permanent Red, and hematoxylin) on dualstained slides were imaged using the Nuance FX imaging system (CRI). Pure chromogen control slides (DAB, Permanent Red, or hematoxylin) were prepared as described above using a single antibody (or no antibody for the hematoxylin control). These control, single color slides were used to generate spectral libraries of each chromogen used in the study. Settings on the microscope and camera were kept consistent for all image cubes taken. Images (at 2009 magnification) were obtained at 20-nm intervals across a range of 420-720 nm to create image cubes which were then spectrally unmixed into two or three individual monochrome images (one for each color) for subsequent image analyses.
Automated image analysis
Pipelines were developed in CellProfiler software (Broad Institute [34, 35] ) to analyze the unmixed monochrome images obtained from the Nuance system. Cell nuclei were 
Statistical analysis
The associations between clinicopathologic parameters in the HG-DCIS and nHG-DCIS cohorts were tested with Fisher's exact test for 2 9 2 or 2 9 3 comparisons. Spearman's correlation test was used to assess the correlations between manual and automated cell counts, as well as the relationship between immune cell populations and clinicopathologic characteristics. Mean differences of immune cell populations in the HG-DCIS and nHG-DCIS cohorts were determined with the Student's t test. Correlation network analyses and maps were visualized in R with the igraph package. Communities of cell types were determined using the walktrap function, which finds densely connected subgraphs (communities) in a graph via random walks. Classification trees were produced using a Recursive Partitioning and Regression Trees (RPART) analysis in R with tenfold cross validation (rpart and rpart.plot libraries). Trees were generated from immune population data combined with clinical parameters. Kaplan-Meier recurrence-free survival curves were calculated and plotted in R using the ''survival'' library and the ''survfit'' function. Differences between curves were compared using the v 2 statistic (''survdiff'' function).
Results
Clinical characteristics of patient cohorts
The clinicopathologic characteristics of DCIS cases in this study are presented in Tables 2 and 3 . The median age for the entire cohort was 47 years (range 26-79 years). Both the HG-DCIS and the nHG-DCIS cohorts showed similar age distributions. The HG-DCIS lesions demonstrated more comedonecrosis and were skewed towards hormone receptor negativity, HER2 positivity, higher proliferation (Ki67), and higher VNPI scores compared to the nHG-DCIS lesions. The median follow-up time for the entire cohort was 7.1 years (range 0.1-16.2 years). There were 18 relapses in this DCIS series, which included six local recurrences of DCIS, eight local/contralateral invasive tumors, and four metastatic events.
The immune landscape of DCIS DCIS samples were stained for immune markers and analyzed using an integrated image analysis approach. The Nuance imaging system unmixes spectra from the various chromogens used and the resulting unmixed images were then analyzed using custom pipelines developed in CellProfiler software. Figure 2 shows examples of cases with low and high numbers of various immune cell infiltrates.
To determine the concordance between automated scoring and manual scoring, subsets of cases were visually scored by a pathologist who was blinded to the automated image analysis results. Cases were selected that spanned a range from low to high counts for the given marker as measured by the automated counting algorithms. Visual scores/counts were highly correlated with the automated counts for single-and two-color stained populations (Fig. 3) . Since TILs are composed mainly of T and B lymphocytes, summing the automated counts for CD4
? and CD8
? cells (T lymphocytes) with CD20 ? cells (B lymphocytes) yielded an automated TIL count. There was good concordance between this automated TIL count and the manual score for TILs (Fig. 3) .
Correlation network maps were constructed to investigate the relationships between immune cell populations in HG-DCIS versus nHG-DCIS (Fig. 4) 
Immune cell populations in HG-DCIS vs nHG-DCIS and correlations with clinicopathologic parameters
The percentages of each immune cell population in nHG-DCIS (gray boxes) and HG-DCIS (white boxes) are shown ? cells) compared to nHG-DCIS. Examining correlations between immune cell populations and clinical characteristics of all 117 DCIS cases, we found that overall, immune infiltrates tended to be correlated with high-risk features (Fig. 5b) . CD68
? macrophages were correlated with high VNPI, palpability, high-grade, comedonecrosis, Ki67 positivity, and HR negativity. Similar results were seen for the Mac387
? cells and the dual positive CD68
? Mac387 ? cells. Interestingly, the CD68
? MRC1 ? cells (M2-type macrophages) were not significantly correlated with any clinical parameters. CD115, the CSF-1 receptor, was expressed on both Tamoxifen only 11 (9) 6 (9) 5 (10) XRT only 29 (25) 18 (28) 11 (21) XRT ? tamoxifen 10 (9) 
Immune cell populations as markers of clinical outcome
Comparing the mean percentages of immune cell populations in cases with a recurrence versus those without, we found no cell types that, by themselves, were associated with outcomes. We then constructed a prognostic model using the RPART function in R. A classification tree was generated using as input 16 immune cell populations along with 8 clinical parameters (grade, VNPI, tumor size, palpable, comedonecrosis, HR status, HER2 status, and DCIS density). Of the 24 input parameters, the best RPART model was built using only 3 immune cell populations: CD8
? HLADR ? cells, CD8
? HLADR -cells and CD115
? cells (Fig. 6a) . This model had an accuracy of 87% (sensitivity = 76%; specificity = 89%). Importantly, all four cases with metastatic recurrences were correctly predicted. Recurrence-free survival curves according to this model are shown in Fig. 6b 
cells, and low CD115
? cells (node 2) were at a low risk for recurrence. There was no significant difference in recurrence-free survival between the nHG-DCIS and the HG-DCIS cohorts (Fig. 6c) , nor when stratified by VNPI (Fig. 6d) .
Discussion
Several studies have shown a clear association between lymphocyte and/or macrophage infiltration and prognosis in human invasive breast cancer; [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] however, the role of these cells in the prognosis of DCIS is unclear. In this study, we characterized the immune landscape of DCIS and asked whether certain populations of immune cells were associated with high-grade DCIS and if these might provide markers and etiology for risk of recurrence. We would like to emphasize that, due to the lack of a validation cohort, this should be considered an exploratory/descriptive study. DCIS tissue sections were stained for a panel of immune markers and analyzed with a multispectral imaging system. Multispectral imaging captures information from multiple wavelengths, not simply the red, green, and blue that our eyes see. This enables the disentangling of multiplex stains even when they are spatially overlapping, a task difficult for the human eye. Our automated image analyses correlated well with visual counts/scores by a pathologist. In particular, summing the automated counts of CD4
? , CD8 ? , and CD20
? lymphocytes correlated well with manual/visual scoring of tumor infiltrating lymphocytes, which can be a tedious process. ? B cells) were higher in HG-DCIS versus nHG-DCIS. This is consistent with previous studies that found increased inflammation associated with high nuclear grade in DCIS [30, 31] . We also observed higher levels of CD68
? macrophages in HG-DCIS, consistent with our earlier study [13] , as well as increased numbers of CD68 ? PCNA ? macrophages, which we have previously reported as being associated with poor outcomes in invasive breast cancer [19] . Finally, we found more FoxP3 ? cells (Treg cells) in HG-DCIS compared to nHG-DCIS.
Although we observed that various immune cell populations were correlated with high-risk features, none of these by themselves were correlated with recurrence events. This is consistent with a recently published study by Thompson et al. [36] ? cell population was more highly correlated with CD8
? cell populations in HG-DCIS compared to nHG-DCIS cases (see Fig. 4 ? cell population. These results suggest that the adaptive immune response may play a role in preventing recurrence in DCIS. An independent validation study is warranted to confirm these results.
DCIS has always been characterized and treated based on pathologic criteria such as nuclear grade and size. More recently, a multigene expression assay, Oncotype DX DCIS, has been developed to predict recurrence risk for DCIS [37] . Interestingly, a study by Knopfelmacher et al. [38] found that a dense chronic inflammatory infiltrate around DCIS, defined as circumferential cuffing of the duct by lymphocytes or plasma cells at least three cell layers in thickness, was associated with a high Oncotype DX DCIS score. However, only 4 of the 45 cases studied had a high score and of these, only 2 showed dense periductal inflammation. As part of a subsequent validation study, we will obtain Oncotype DX DCIS scores on all cases to further define specific immune populations that may be associated with the Oncotype DX DCIS score.
The goal of the current study was to provide more insight into the biology of DCIS-at the level of the immune microenvironment-in order to catalyze new treatment approaches. These data support a way to identify the DCIS with highest risk for recurrence and suggest that immunotherapeutic strategies could be efficacious. The recent analysis done by Narod et al. shows that our current approach of treating DCIS with surgery followed by radiation therapy is not sufficient for the rare cases of DCIS that lead to breast cancer mortality [6] . The immune microenvironment is clearly different in high-risk lesions and offers an opportunity to find targeted ways to treat high-risk DCIS. We have initiated studies to determine whether we can activate the immune system and reverse these lesions to address the specific mortality risk these lesions pose.
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